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Combination of Shwachman-Diamond syndrome genetic mutations and cystic ﬁbrosis carrier mutations
can account for severe morbidity and early mortality in a patient with Shwachman-Diamond syndrome.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Shwachman-Diamond syndrome (SDS) is autosomal recessive
presenting in infancy with exocrine pancreatic insufﬁciency, bone
marrow failure, growth and skeletal abnormalities such as thoracic
dystrophy and failure to thrive (FTT).1,2 It affects 1 in 75,000.3 In 90%
of patients with SDS the genetic mutations have been localized to
chromosome 7(7p10–7q11).3,4
The mean age for diagnosis of SDS is 1 year with projected
survival of most patients into adult years.5 During infancy the
main causes of increased morbidity and mortality are malab-
sorption, infections and thoracic dystrophy (rib cage abnormalities
with shortened ribs and a narrow rib cage).2,5 The leading causes
of morbidity and mortality later in life are hematological abnor-
malities and treatment of the hematological complications.5
Children with SDS have an increased risk for developing myelo-
dysplastic syndrome and acute myeloid leukemia (AML) with poor
prognosis.3
Cystic ﬁbrosis (CF) is an autosomal recessive disease common
among Caucasians of European descent. The defective gene isolated
is on the long arm of chromosome 7. Delta F508 is the most
common mutation among Caucasians and I1027T has been studied
as a delta F508-I1027 haplotype consisting of a cis-association of
the two mutations.6,7 Cystic ﬁbrosis carriers do not show any
manifestations of the disease.8 Our case report is uniquewith a very
early age of diagnosis due to severe morbidity not usually seen. OurPulmonology, University of
ter Drive, Room L2221, Annhypothesis is that the combination of SDS genetic mutations and CF
carrier mutations led to the severe morbidity and early mortality of
our case.
2. Case report
ZM was born at 42 weeks gestation with profound hypotonia,
poor suckling and leukopenia with subsequent pancytopenia. Birth
weight was 2.6 kg (w5th percentile). Family history was notable for
a half-brother with septo-optic dysplasia. No family history of
consanguinity.
At three months of age, he was hospitalized for four weeks with
respiratory insufﬁciency and hypoxia, persistent steatorrhea and
FTT. Genetic testing for SDS and CF identiﬁed two separate
mutations for SDS: C.258 2T-to-C and C.258 1G-to-C (compound
heterozygote for SDS) leading to the diagnosis of SDS and two
genetic mutations for CF (delta F508 and I1027T) identiﬁed were
determined to be of maternal origin. Sweat chloride test was
negative. Low fecal elastase demonstrated severe pancreatic
insufﬁciency. He had severe FTT despite pancreatic enzyme
supplementation.
He was rehospitalized at ﬁve months of age for worsening
hypoxia and respiratory distress secondary to RSV bronchiolitis. He
developed respiratory failure requiring mechanical ventilation,
pneumothorax and septic shock. He was eventually weaned to
oxygen via nasal cannula. He continued to have respiratory distress,
severe FTT (up 205 g from birth weight) and cyclic pancytopenia.
He was transferred to our hospital after three weeks for further
work up and management.
Throughout the six-week hospitalization he was persistently
tachypneic (respiratory rates 60–80 s). Chest X-rays demonstrated
hypoplastic thorax and short ribs. High resolution CT of the chest
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ostosis, and fatty inﬁltrate of the pancreas. He was kept on intra-
venous (IV) total parental nutrition due to poor wound healing of G
Tube site. Episodes of cyclic pancytopenia were often associated
with fever and multiple infections with methicillin resistant Staph
epidermidis and Staph aureus and Pseudomonas aeruginosa.
He received numerous platelet and packed RBC transfusions.
Bone marrow biopsy demonstrated 46 XY with hypocellularity,
depressed white cell lineages without clonal or leukemic abnor-
malities. He had two subsequent admissions for recurrence of fever
and diarrhea and was treated with antibiotics.
He was readmitted at eight months of age within a day of
discharge, with fever, respiratory distress and worsening hypoxia.
He was not considered for bone marrow transplant due to poor
nutrition, worsening hypoxia and severe restrictive lung disease.
He succumbed at eight months of age due to respiratory failure,
acidosis, persistent fever and a precipitous anemia.
3. Discussion
SDS is an autosomal recessive syndromewithmedian survival of
35 years.5 Although genetic mutation is identiﬁable in up to 90% of
patients, a correlation between genotype and phenotype or disease
severity has not been found.9 Management for patients with SDS is
pancreatic enzyme replacement, monitoring of white counts,
management of neutropenia with granulocyte colony stimulating
factor, management of anemia and thrombocytopenia with red
blood cell and platelet transfusions. Hemopoetic stem cell trans-
plantation is currently the only treatment for bone marrow
failure.10 Our patient died in infancy, despite aggressive manage-
ment secondary to severe restrictive lung disease, profound neu-
tropenia, anemia, recurrent infections and poor nutritional status.
The severity of his SDS is striking complicated by compound CF
carrier status. We hypothesize that the two mutations of cysticﬁbrosis that were present on the 7th chromosome exon 10 site
found in close proximity to the SDSmutations at chromosome 7q11,
may have contributed to the severity of his SDS course. This is the
ﬁrst report that documents a case with severe SDS and 2 mutations
for CF that are originating from one parent.
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